Eupraxia reports 52-week data from highest dose cohort of EP-104GI in RESOLVE trial
The company said 9 of 14 patients across cohorts 5-9 remained in clinical remission at 52 weeks after a single dose, with no treatment-related serious adverse events reported.
Eupraxia Pharmaceuticals Inc. announced updated data on September 30, 2026 from the Phase 1b/2a portion of its RESOLVE trial evaluating EP-104GI in Eosinophilic Esophagitis (EoE). In the highest dose group, Cohort 9, the mean reduction in SDI at 36 and 52 weeks was 3.0 at both timepoints1. In the second highest dose group, Cohort 8b, new data showed the mean EoEHSS Stage and Grade reductions at week 36 were -0.26 (SD=0.13) and -0.27 (SD=0.20)1.
Across cohorts 5 through 9, the company reported clinical remission rates over time: at 12 weeks, 53% (10/19) of patients achieved clinical remission; at 24 weeks, 78% (14/18) maintained clinical remission; at 36 weeks, 61% (11/18) maintained clinical remission; and at 52 weeks, 64% (9/14) maintained clinical remission1.
On safety, the company said there were no treatment-emergent or procedure related SAEs, no cases of oropharyngeal candidiasis, and no cases of adrenal insufficiency or glucose derangement1. It added that EP-104GI has been generally well tolerated at all dose levels, including the highest dose of 8 mg/site at 20 injection sites in Cohort 91.
The RESOLVE trial's Phase 1b/2a portion is described as a multicenter, open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with a history of confirmed active EoE1. Separately, the Phase 2b portion of the trial, a randomized placebo-controlled study, is currently recruiting both the 120mg and 160mg doses, with interim data expected in December 20261.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.